Effect of excipients on the efficacy and safety of external polycomponent products
https://doi.org/10.21518/ms2026-082
Abstract
Over the past decade, there has been an increase in the number of patients suffering from chronic dermatoses complicated by secondary infections. A number of factors contribute to an increase in the risks of dermatoses, both from the external environment (temperature and humidity, cleanliness of air and drinking water, food, stress), and the state of the human body (age, gender, hormonal background, the presence of concomitant diseases). An important factor determining the risk of skin pathology is the state of the microbiota, which depends, among other things, on the use of antiseptics, antibiotics, including topical ones. Insufficient activity of antimicrobial treatment may be accompanied by the development of dysbiosis, the appearance of antibiotic-resistant strains. One of the main directions of treatment of combined skin pathology is the use of polycomponent drugs in the form of creams and ointments. A combination of three components is widely used: betamethasone dipropionate, gentamicin sulfate, and clotrimazole. The pharmaceutical market of the Russian Federation is attended by both the original Triderm drug and generic drugs, in particular, Akriderm GK. There are some differences between these drugs regarding the composition of the excipients, since the developers of the ointment and cream Acryderm GC aimed to increase the penetration of antibiotic and antimycotic into the skin, increasing the effectiveness of treatment, which may reduce the risks of antibiotic resistance. At the same time, there is a study that shows the therapeutic equivalence of Akriderm GK to Triderm cream in the treatment of eczema. Akriderm GK is an interchangeable drug for Triderm cream, and can be used in the clinic as an effective, safe and cost-effective replacement for an imported drug. In this review we summarized the scientific evidence from 39 domestic and foreign research reports on both the treatment of dermatoses and the pharmacological features of agents used for the treatment of inflammatory skin diseases.
About the Author
O. V. Filippova
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Olga V. Filippova, Dr. Sci. (Med.), Professor of the Department of Industrial Pharmacy
8, Bldg. 2, Trubetskaya St., Moscow, 119991
References
1. Lvov AN, Kruglova LS, Zagrtdinova RM, Kovaleva YuS, Kokhan MM, Matushevskaya EV et al. The Place of Topical Combined Multicomponent Drugs in the Therapy of Complicated Dermatoses (Resolution of the Expert Council). Medical Alphabet. 2024;(25):103–107. (In Russ.) https://doi.org/10.33667/2078-5631-2024-25-103-107.
2. Pomerantsev ON, Potekaev NN. The incidence of skin and subcutaneous fat diseases as a sociomedical problem. Klinicheskaya Dermatologiya i Venerologiya. 2013;11(6):4–6. (In Russ.) Available at: https://www.mediasphera.ru/issues/klinicheskaya-dermatologiya-i-venerologiya/2013/6/031997-2849201361.
3. Kubanov AA, Bogdanova EV. Epidemiology of diseases of the skin and subcutaneous tissue and specialized medical care provided in three age groups of the population in 2010–2020 in the Russian Federation. National Health Care (Russia). 2022;3(1):15–24. (In Russ.) https://doi.org/10.47093/2713-069X.2022.3.1.15-24.
4. Mattson G, Coates S, Twigg AR. Patient Perceptions of Climate Change Impacts on Atopic Dermatitis: Cross-Sectional Survey Study. JMIR Dermatol. 2026;9:e80679. https://doi.org/10.2196/80679.
5. Singh N, Schikowski T, Krutmann J. Air Pollution and Skin Diseases: A Systematic Review of Epidemiological Evidence. Am J Clin Dermatol. 2026. https://doi.org/10.1007/s40257-026-01006-5.
6. Klimitz FJ, Shen Y, Repetto F, Brown S, Knoedler L, Ko CJ et al. Keratinocytes as active regulators of cutaneous and mucosal immunity: a systematic review across inflammatory epithelial disorders. Front Immunol. 2025;16:1694066. https://doi.org/10.3389/fimmu.2025.1694066.
7. Tabata K, Ikarashi N, Yoshida R, Shinozaki Y, Kato Y, Kon R et al. High-fat diet exacerbates atopic dermatitis through alterations in the gut microbiome. J Nutr Biochem. 2026;148:110164. https://doi.org/10.1016/j.jnutbio.2025.110164.
8. Barrea L, Nappi F, Di Somma C, Savanelli MC, Falco A, Balato A et al. Environmental Risk Factors in Psoriasis: The Point of View of the Nutritionist. Int J Environ Res Public Health. 2016;13(5):743. https://doi.org/10.3390/ijerph13070743.
9. Balieva F, Schut C, Szabó C, Sampogna F, Dalgard FJ, Altunay IK et al.; ESDaP Study collaborators. Stress in dermatology patients: A multicenter observational study of 8295 outpatients and controls from 22 European clinics. JAAD Int. 2025;25:69–77. https://doi.org/10.1016/j.jdin.2025.12.005.
10. Mar K, Rivers JK. The Mind Body Connection in Dermatologic Conditions: A Literature Review. J Cutan Med Surg. 2023;27(6):628–640. https://doi.org/10.1177/12034754231204295.
11. Roster K, Fleshner L, Karatas TB, Ecanow A, Sayegh A, Farabi B, Marmon S. Menopause and Common Dermatoses: A Systematic Review. Am J Clin Dermatol. 2026;27(1):67–84. https://doi.org/10.1007/s40257-025-00994-0.
12. Byrd AL, Belkaid Y, Segre JA. The human skin microbiome. Nat Rev Microbiol. 2018;16(3):143–155. https://doi.org/10.1038/nrmicro.2017.157.
13. Özdemіr E, Öksüz L. Effect of Staphylococcus aureus colonization and immune defects on the pathogenesis of atopic dermatitis. Arch Microbiol. 2024;206(10):410. https://doi.org/10.1007/s00203-024-04134-w.
14. Wrześniewska M, Wołoszczak J, Świrkosz G, Szyller H, Gomułka K. The Role of the Microbiota in the Pathogenesis and Treatment of Atopic DermatitisA Literature Review. Int J Mol Sci. 2024;25(12):6539. https://doi.org/10.3390/ijms25126539.
15. Gonzalez ME, Schaffer JV, Orlow SJ, Gao Z, Li H, Alekseyenko AV, Blaser MJ. Cutaneous microbiome effects of fluticasone propionate cream and adjunctive bleach baths in childhood atopic dermatitis. J Am Acad Dermatol. 2016;75(3):481–493.e8. https://doi.org/10.1016/j.jaad.2016.04.066.
16. Wojciechowska K, Dos Santos Szewczyk K. The Skin Microbiome and Bioactive Compounds: Mechanisms of Modulation, Dysbiosis, and Dermatological Implications. Molecules. 2025;30(22):4363. https://doi.org/10.3390/molecules30224363.
17. Polak K, Jobbágy A, Muszyński T, Wojciechowska K, Frątczak A, Bánvölgyi A et al. Microbiome Modulation as a Therapeutic Approach in Chronic Skin Diseases. Biomedicines. 2021;9(10):1436. https://doi.org/10.3390/biomedicines9101436.
18. Kong HH, Segre JA. Skin microbiome: looking back to move forward. J Invest Dermatol. 2012;132(3):933–939. https://doi.org/10.1038/jid.2011.417.
19. Kolb L, Ferrer-Bruker SJ. Atopic Dermatitis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025. Available at: https://www.ncbi.nlm.nih.gov/books/NBK448071.
20. Shperling NV. The use of combined topical glucocorticosteroids in infectious dermatitis of the folds. Meditsinskiy Sovet. 2025;19(13):269–272. (In Russ.) https://doi.org/10.21518/ms2025-263.
21. Olekson MA, Rose LF, Carlsson AH, Fletcher JL, Leung KP, Chan RK. Ultrahigh dose gentamicin alters inflammation and angiogenesis in vivo and in vitro. Wound Repair Regen. 2017;25(4):632–640. https://doi.org/10.1111/wrr.12557.
22. Lee AH, Swaim SF, Yang ST, Wilken LO. Effects of gentamicin solution and cream on the healing of open wounds. Am J Vet Res. 1984;45(8):1487–1492. Available at: https://pubmed.ncbi.nlm.nih.gov/6476559.
23. Sergeev YuV. Triderm: taxtics of the therapy of inflammatory dermatoses caused by fungal and mixed infection. Immunopathology, Allergology, Infectology. 2004;(3):64–73. (In Russ.) Available at: https://www.immunopathology.com/ru/article.php?carticle=234.
24. Anisimova LA, Sidorenko OA. Topical steroid drugs Elokom and Triderm in the treatment of atopic dermatitis in children. RMJ. 2000;(13):570. Available at: https://www.rmj.ru/articles/pediatriya/Topicheskie_steroidnye_preparaty_elokom_i_triderm_v_terapii_atopicheskogo_dermatita_u_detey.
25. Komaristov IA. Experience of using Triderm preparations. Military Medical Journal. 2000;(5):40–41. (In Russ.) Available at: http://elib.fesmu.ru/Article.aspx?id=46749&ysclid=mmx9ofb17v983981987.
26. Ordoñez-Toro A, Montero-Vilchez T, Muñoz-Baeza J, Sanabria-De-la-Torre R, Buendia-Eisman A, Arias-Santiago S. The Assessment of Skin Homeostasis Changes after Using Different Types of Excipients in Healthy Individuals. Int J Environ Res Public Health. 2022;19(24):16678. https://doi.org/10.3390/ijerph192416678.
27. Bayan MF, Chandrasekaran B, Alyami MH. Development and Characterization of Econazole Topical Gel. Gels. 2023;9(12):929. https://doi.org/10.3390/gels9120929.
28. Otake H, Mano Y, Deguchi S, Ogata F, Kawasaki N, Nagai N. Effect of Ointment Base on the Skin Wound-Healing Deficits in Streptozotocin-Induced Diabetic Rat. Biol Pharm Bull. 2023;46(5):707–712. https://doi.org/10.1248/bpb.b22-00871.
29. Kaushik V, Schatton W, Keck CM. Influence of type of vehicle on dermal penetration efficacy of hydrophilic, amphiphilic, lipophilic model drugs. Eur J Pharm Biopharm. 2024;200:114305. https://doi.org/10.1016/j.ejpb.2024.114305.
30. Ляпунов НА, Зуев АП, Ломакина ВД, Жемерова ЕГ, Юрченко НИ, Дунай ЕВ, Емшанова СВ. Фармацевтическая композиция противовоспалительного и антимикробного действия в форме мази на гидрофобной основе для лечения кожных заболеваний (варианты). Патент RU 2325912 C1, 10.06.2008. Режим доступа: https://patents.google.com/patent/RU2325912C1/ru.
31. Bayan MF, Chandrasekaran B, Alyami MH. Development and Characterization of Econazole Topical Gel. Gels. 2023;9(12):929. https://doi.org/10.3390/gels9120929.
32. Dukhanin AS. PH value of the base of topical drug product: the choice of the optimal value and the role of buffer system. Klinicheskaya Dermatologiya i Venerologiya. 2016;15(2):47–52. (In Russ.) https://doi.org/10.17116/klinderma201615247-52.
33. Molokhova YeI, Sorokina YuV. Comparative investigation of rheological characteristics of the original drug Triderm and its generics in the form of cream. Antibiotiki i Khimioterapiya. 2014;59(5-6):3–5. (In Russ.) Available at: https://www.elibrary.ru/syjrfb.
34. Grammatikova NE. Comparative Study of In Vitro Antimicrobial Activity of Combined Topical Dosage Forms of Betamethasone, Gentamicin, and Clotrimazole. Pharmaceutical Chemistry Journal. 2019;53(10):45–49. (In Russ.) https://doi.org/10.30906/0023-1134-2019-53-10-45-49.
35. Khaldin AA, Zhukova OV. Open randomized controlled trial to study the effectiveness and safety of domestic (Russian) versus foreign multicomponent topical preparations for the treatment of eczema. Klinicheskaya Dermatologiya i Venerologiya. 2019;18(3):327–337. (In Russ.) https://doi.org/10.17116/klinderma201918031327.
36. Khardikova SA. Efficacy and tolerability of various forms of Akriderm GK in routine dermatological practice. Klinicheskaya Dermatologiya i Venerologiya. 2016;15(5):55–61. (In Russ.) https://doi.org/10.17116/klinderma201615555-61.
37. Gavrilova LA. Clinical experience of using Akriderm GK cream in a patient with toxicoderma. South Ural Medical Journal. 2016;(2):4–7. (In Russ.) Available at: https://elibrary.ru/yngnnp.
38. Matushevskaya YeV, Shakurov IG, Khismatulin ZR. Effectiveness and tolerance of Akriderm preparations in dermatovenereologic practice. Klinicheskaya Dermatologiya i Venerologiya. 2008;(2):1–4. (In Russ.) Available at: https://www.akrikhin.ru/upload/iblock/0bb/Matushevskaya.pdf.
39. Filimonkova NN, Bakhlykova YA. A combined topical therapy of chronic dermatoses. Vestnik Dermatologii i Venerologii. 2015;91(3):147–152. (In Russ.) https://doi.org/10.25208/0042-4609-2015-91-3-147-152.
Review
For citations:
Filippova OV. Effect of excipients on the efficacy and safety of external polycomponent products. Meditsinskiy sovet = Medical Council. 2026;(2):57-62. (In Russ.) https://doi.org/10.21518/ms2026-082
Views:
62
JATS XML
Email this article 